Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company pioneering targeted therapies for cancers driven by RAS mutations. This page serves as the definitive source for verified news and developments related to the company's precision oncology programs.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements in RAS pathway inhibition. Our curated collection includes press releases on drug discovery breakthroughs, partnership announcements, and peer-reviewed research findings.
Key focus areas include updates on the company's RAS(ON) inhibitor portfolio, mTOR signaling developments, and strategic collaborations advancing cancer treatment innovation. All content is vetted for accuracy and relevance to provide reliable insights into RVMD's evolving pipeline.
Bookmark this page for structured access to essential updates about Revolution Medicines' progress in addressing unmet needs in oncology through its evolution-inspired therapeutic approaches.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has scheduled its Q1 2025 financial results announcement for May 7, 2025, after market close.
The company's senior management team will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss:
- First quarter 2025 financial performance
- Updates on corporate progress
Investors and interested parties can access the live webcast through the company's investor relations website at ir.revmed.com/events-and-presentations. A replay of the webcast will remain available on the website for at least 14 days following the live presentation.
Revolution Medicines (RVMD) has presented initial clinical data for zoldonrasib (RMC-9805), their RAS(ON) G12D-selective inhibitor, in treating KRAS G12D mutant non-small cell lung cancer (NSCLC) patients. The Phase 1 study results were presented at the 2025 AACR Annual Meeting.
Key findings from the study with 90 solid tumor patients treated with 1200 mg once daily dose showed:
- 61% objective response rate in 18 efficacy-evaluable NSCLC patients
- 89% disease control rate
- 98% mean dose intensity with no dose limiting toxicities
- Acceptable safety profile with mostly Grade 1 or 2 adverse events
Common treatment-related adverse events included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%). Only 2% of patients experienced Grade 3 events, which resolved after dose interruption.
Revolution Medicines (RVMD) announced 11 presentations at the upcoming 2025 AACR Annual Meeting in Chicago (April 25-30, 2025). The highlight will be the first clinical data presentation of zoldonrasib, their RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer patients during a late-breaking oral session.
Key presentations include preliminary safety and antitumor activity data of zoldonrasib in KRAS G12D NSCLC patients, the discovery of RMC-5127 (a RAS(ON) G12V-selective inhibitor), and clinical activity data of daraxonrasib in RAS mutant NSCLC. Additional presentations will cover resistance mechanisms, combination therapies, and immune response in various cancer types including pancreatic and colorectal cancers.
Revolution Medicines (RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in two major investor conferences in April 2025.
The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in fireside chats at the following events:
- Needham 24th Annual Virtual Healthcare Conference on Monday, April 7 at 2:15 p.m. ET
- Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9 at 1:00 p.m. ET
Live webcasts and replays of both events will be accessible through the company's investor relations website for a minimum of 14 days following the presentations.
Revolution Medicines (RVMD) reported its Q4 and full year 2024 financial results, highlighting progress in its RAS-focused cancer drug development programs. The company ended Q4 2024 with a net loss of $194.6M, compared to $161.5M in Q4 2023, while full-year 2024 net loss was $600.1M.
Key developments include advancing Phase 3 trials for daraxonrasib in pancreatic and lung cancers. The company expects to complete enrollment in the RASolute 302 trial for metastatic pancreatic cancer in 2025, with data readout in 2026. Two additional registrational trials for pancreatic cancer are planned for H2 2025.
Financially, RVMD strengthened its position through an $823M public equity offering in December 2024, ending the year with $2.3B in cash. The company projects 2025 GAAP net loss between $840M-$900M and expects current funds to support operations into H2 2027.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.
The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:
- TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET
Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. Interested parties can view a replay of the webcast on the same platform for at least 14 days following the conference.
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, at 10:30 a.m. PT.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. A replay of the presentation will remain available on the website for a minimum of 14 days following the conference.
Revolution Medicines (RVMD) has successfully closed its upsized public offering, raising $862.5 million in gross proceeds. The offering consisted of 16,576,088 shares of common stock at $46.00 per share and pre-funded warrants to purchase 2,173,917 shares at $45.9999 per share. The total includes 2,445,652 additional shares from the full exercise of the underwriters' option.
The offering was managed by J.P. Morgan, TD Cowen, Goldman Sachs & Co. , and Guggenheim Securities as joint book-running managers, with UBS Investment Bank acting as lead manager.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
